C
The startup develops a biomolecule reverse vaccinology technology utilizing modified outer membrane vesicles to create safe and sustainable vaccines and antibodies against infections. This platform enables laboratories to efficiently produce effective vaccines and immuno-therapeutics for pre-clinical research and development.
Siena, Italy
Updated 2 months ago
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a biomolecule reverse vaccinology technology utilizing modified outer membrane vesicles to create safe and sustainable vaccines and antibodies against infections. This platform enables laboratories to efficiently produce effective vaccines and immuno-therapeutics for pre-clinical research and development.